• Users Online: 46985
  • Home
  • Print this page
  • Email this page
This article has been cited by
1Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence
Debdulal Chakraborty,Soumen Mondal,Subhendu Boral,Arnab Das,Tushar Kanti Sinha,Saptorshi Majumdar,Ranabir Bhattacharya,Ritobroto Maitra
Clinical Ophthalmology.2023;Volume 17()1067
[DOI]
2Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence
Thirumurthy Velpandian,Ujjalkumar S. Das
Clinical Ophthalmology.2016;Volume 17()385
[DOI]
3Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy – a systematic approach to identify and characterize data sources
Vincent Daien,Bora M. Eldem,James S. Talks,Jean-Francois Korobelnik,Paul Mitchell,Robert P. Finger,Taiji Sakamoto,Tien Yin Wong,Obaro Evuarherhe,Gemma Carter,Joao Carrasco
BMC Ophthalmology.2019;19(1)385
[DOI]
4Age-Related Macular Degeneration
Sonia Mehta
Primary Care: Clinics in Office Practice.2015;42(3)377
[DOI]
5Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis
Justus G. Garweg,Christin Gerhardt
Graefe's Archive for Clinical and Experimental Ophthalmology.2021;259(8)2181
[DOI]
6LC/MS Assessment of Glycoform Clearance of A Biotherapeutic MAb in Rabbit Ocular Tissues
Shiyu Dong,Linzhi Chen,Achim Sauer,Lars Dittus
Journal of Pharmaceutical Sciences.2023;112(8)2285
[DOI]
7Clinical Efficacy and Safety of Current Interventions for Choroidal Neovascularization Associated with Rare Diseases: A Systematic Literature Review
Natalie Bennett,Lokho John,Nishkarsh Likhar,Rumjhum Agrawal,Winfried M. Amoaku
Advances in Therapy.2018;35(5)591
[DOI]
8ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION IN THE ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ERA
Emily K. Tam,Pamela Golchet,Madeline Yung,Francis C. DeCroos,Marc Spirn,Lydia Lehmann-Clarke,Aude Ambresin,Irena Tsui
Retina.2018;38(2)292
[DOI]
9ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION IN THE ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ERA
Samhitha Gudla,Divya Tenneti,Makrand Pande,Srinivas M. Tipparaju
Retina.2018;38(2)83
[DOI]
10Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats
Paulina Jakubiak,Rubén Alvarez-Sánchez,Matthias Fueth,Olaf Broders,Hubert Kettenberger,Kay Stubenrauch,Antonello Caruso
Molecular Pharmaceutics.2021;18(6)2208
[DOI]
11Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study
Asim K. Ghosh,Usha S. Nikumbh,Chaitanya K. Shukla,Rohit S. Laul,Abhishek Dixit,Santosh K. Mahapatra,Sameera Nayak,Urmil M. Shah,Sandeep Parwal,Narendran Venkatapathy,Natasha Radhakrishnan,Anup Kelgaonkar,Sandeep Saxena,Divyansh Mishra,Vivek Pravin Dave,Perwez Khan,Manojkumar R. Saswade,Malli S. Shantilal,Kim Ramasamy,Smitha Sreekanta,Mandodari Rajurkar,Maulik Doshi,Sapan Behera,Piyush Patel,Shilpi Dhawan,Lalit Lakhwani
Ophthalmology and Therapy.2024;18(6)2208
[DOI]
12Pretreatment of RPE Cells with Lutein Can Mitigate Bevacizumab-Induced Increases in Angiogenin and bFGF
Natàlia Vilà,Jacqueline Coblentz,Carlos Moreira-Neto,Vasco Bravo-Filho,Pablo Zoroquiain,Miguel N. Burnier Jr.
Ophthalmic Research.2017;57(1)48
[DOI]
13Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know
Azka Ali,Ankit A. Shah,Lauren J. Jeang,Kyle S. Fallgatter,Thomas J. George,David L. DeRemer
Cancer Treatment Reviews.2022;105(1)102376
[DOI]
14Targeting angiogenesis in oncology, ophthalmology and beyond
Yihai Cao,Robert Langer,Napoleone Ferrara
Nature Reviews Drug Discovery.2023;22(6)476
[DOI]
15Cell-based approaches towards treating age-related macular degeneration
Alireza Baradaran-Rafii,Masoumeh Sarvari,Sepideh Alavi-Moghadam,Moloud Payab,Parisa Goodarzi,Hamid Reza Aghayan,Bagher Larijani,Mostafa Rezaei-Tavirani,Mahmood Biglar,Babak Arjmand
Cell and Tissue Banking.2020;21(3)339
[DOI]
16Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human Limbal Epithelial Cells in Vitro
Maria Notara,Anna Lentzsch,Thomas Clahsen,Sara Behboudifard,Gabriele Braun,Claus Cursiefen
Journal of Clinical Medicine.2019;8(11)1925
[DOI]
17Challenges and strategies for the delivery of biologics to the cornea
M. Wels,D. Roels,K. Raemdonck,S.C. De Smedt,F. Sauvage
Journal of Controlled Release.2021;333(11)560
[DOI]
18Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration
Semra Ozdemir,Eric Finkelstein,Jia Jia Lee,Issac Horng Khit Too,Kelvin Yi Chong Teo,Anna Chen Sim Tan,Tien Yin Wong,Gemmy Chui Ming Cheung,Marie-Helene Errera
PLOS ONE.2022;17(8)e0272301
[DOI]
19Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina
Irene Bravo-Osuna,Vanessa Andrés-Guerrero,Alicia Arranz-Romera,Sergio Esteban-Pérez,Irene T. Molina-Martínez,Rocío Herrero-Vanrell
Advanced Drug Delivery Reviews.2018;126(8)127
[DOI]
20Effect of subconjunctival Bevacizumab injection on the outcome of Ahmed glaucoma valve implantation: a randomized control trial
Arezoo Miraftabi,Naveed Nilforushan,Mina Darghahi,Sayyed Amirpooya Alemzadeh,Mohammad Parsamanesh,Maryam Yadgari
Clinical & Experimental Ophthalmology.2018;46(7)750
[DOI]
21Reduced occurrence of programmed cell death and gliosis in the retinas of juvenile rabbits after short-term treatment with intravitreous bevacizumab
Maria Alice Fusco,André Luís Freire Portes,Silvana Allodi,Haroldo Vieira de Moraes Junior,Mário Luiz Ribeiro Monteiro,Nádia Campos de Oliveira Miguel
Clinics.2012;67(1)61
[DOI]
22The Risk of Non-arteritic Ischemic Optic Neuropathy Post-intravitreal Bevacizumab Injection
Nasser A Fugara,Zaineh A Shawareb,Nancy K Rakkad,Manar L Barhoum,Bana A Shawareb,Myrna M Al-Madani,Mousa V Al-Madani
Cureus.2022;67(1)61
[DOI]
23Bevacizumab tested for treatment of knee osteoarthritis via inhibition of synovial vascular hyperplasia in rabbits
Wei Li,Jianjing Lin,Zhanwei Wang,Shiyou Ren,Xiao Wu,Fei Yu,Jian Weng,Hui Zeng
Journal of Orthopaedic Translation.2019;19(1)38
[DOI]
24Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration
Ciro Costagliola,Luca Agnifili,Barbara Arcidiacono,Sarah Duse,Vincenzo Fasanella,Rodolfo Mastropasqua,Marco Verolino,Francesco Semeraro
Expert Opinion on Biological Therapy.2012;12(10)1299
[DOI]
25Antiproliferative, Apoptotic, and Autophagic Activity of Ranibizumab, Bevacizumab, Pegaptanib, and Aflibercept on Fibroblasts: Implication for Choroidal Neovascularization
Lyubomyr Lytvynchuk,Andrii Sergienko,Galina Lavrenchuk,Goran Petrovski
Journal of Ophthalmology.2015;2015(10)1
[DOI]
26Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma
Vanessa Andrés-Guerrero,Lucía Perucho-González,Julián García-Feijoo,Laura Morales-Fernández,Federico Saenz-Francés,Rocío Herrero-Vanrell,Luis Pablo Júlvez,Vicente Polo Llorens,José María Martínez-de-la-Casa,Anastasios-Georgios P. Konstas
Advances in Therapy.2017;34(2)378
[DOI]
27A comparison between the effects of two liposome-encapsulated bevacizumab formulations on ocular neovascularization inhibition
Maryam Malakouti–Nejad,Daniela Monti,Susi Burgalassi,Hassan Bardania,Elahe Elahi,Dina Morshedi
Colloids and Surfaces B: Biointerfaces.2024;234(2)113708
[DOI]
28Mapping of drug-related problems among older adults conciliating medical and pharmaceutical approaches
Marie-Laure Laroche,Thi Hong Van Ngo,Caroline Sirois,Amélie Daveluy,Michel Guillaumin,Marie-Blanche Valnet-Rabier,Muriel Grau,Barbara Roux,Louis Merle
European Geriatric Medicine.2021;12(3)485
[DOI]
29Factors Predicting Treatment Response in Anti-Vascular Endothelial Growth Factor Naïve Diabetic Macular Edema Patients Treated with Intravitreal Bevacizumab
Alastair David Bezzina,Francis Carbonaro
Journal of Ocular Pharmacology and Therapeutics.2019;35(10)551
[DOI]
30Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study
Shashikant Sharma,Vishali Gupta,Aniruddha Maiti,Sribhargava Natesh,Sandeep Saxena,Vivek Dave,Vimal Parmar,Raju Sampangi,Hemanth Murthy,Sandhya Dharwadkar,Naresh Kumar Yadav,Shrinivas Joshi,Rahul Mayor,Dhanashree Ratra,Soumyava Basu,Neha Goel,Alok Chaturvedi,Ronak Patel,Vinu Jose
International Journal of Retina and Vitreous.2021;7(1)551
[DOI]
31Next generation therapeutics for retinal neurodegenerative diseases
Matthew B. Appell,Jahnavi Pejavar,Ashwin Pasupathy,Sri Vishnu Kiran Rompicharla,Saed Abbasi,Kiersten Malmberg,Patricia Kolodziejski,Laura M. Ensign
Journal of Controlled Release.2024;367(1)708
[DOI]
32Combined therapy in diabetic macular edema
J.H. González-Cortés,J.J. Toledo-Negrete,K. Butrón-Valdez,V. Zapata-Elizondo,B.O. Martínez-Gamero,E.E. Treviño-Cavazos,J.D. Guerra-Leal,J. Mohamed-Hamsho
Medicina Universitaria.2015;17(68)153
[DOI]
33Bevacizumab for eye diseases – Legal, regulatory, and ethical overview
Vinu Jose,Swetha Radhakrishna,Parag Pipalava,Inderjeet Singh
Indian Journal of Pharmacology.2019;51(6)377
[DOI]
34Faricimab in the Treatment Landscape for Retinal Diseases: A Review
Anna K Wu,David D Chong,Rishi P Singh
US Ophthalmic Review.2022;16(2)92
[DOI]
35Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy
K Ghasemi Falavarjani,M Hashemi,M Modarres,A Hadavand Khani
Eye.2014;28(5)576
[DOI]
36Subconjunctival Bevacizumab Immediately After Excision of Primary Pterygium: The First Clinical Trial
Abdollah Shenasi,Farideh Mousavi,Solmaz Shoa-Ahari,Babak Rahimi-Ardabili,Rohollah Fadaei Fouladi
Cornea.2011;30(11)1219
[DOI]
37Changing vision: a review of pharmacogenetic studies for treatment response in age-related macular degeneration patients
Janan Arslan,Paul N Baird
Pharmacogenomics.2018;19(5)435
[DOI]
38Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders
Abraham Hang,Samuel Feldman,Aana P. Amin,Jorge A. Rivas Ochoa,Susanna S. Park
Pharmaceuticals.2023;16(8)1140
[DOI]
39Effects of a human VEGF antibody (Bevacizumab) on deprivation myopia and choroidal thickness in the chicken
Ute Mathis,Focke Ziemssen,Frank Schaeffel
Experimental Eye Research.2014;127(8)161
[DOI]
40Bevacizumab for ocular neovascular diseases: a systematic review
Regis Bruni Andriolo,Maria Eduarda Puga,Rubens Belfort Júnior,Álvaro Nagib Atallah
Sao Paulo Medical Journal.2009;127(2)84
[DOI]
41Hydrogel Biomaterials for Application in Ocular Drug Delivery
Courtney R. Lynch,Pierre P. D. Kondiah,Yahya E. Choonara,Lisa C. du Toit,Naseer Ally,Viness Pillay
Frontiers in Bioengineering and Biotechnology.2020;8(2)84
[DOI]
42Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis
Melanie Lipp,Franziska Bucher,Anand Parthasarathy,Deniz Hos,Jasmine Onderka,Claus Cursiefen,Felix Bock
Graefe's Archive for Clinical and Experimental Ophthalmology.2014;252(6)943
[DOI]

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal